IMA
NASDAQImageneBio Inc.
Price$5.44-0.33 (-5.72%)
2026-04-142026-07-17
News · 26 weeks43-57%
2026-01-182026-07-12
Mix2290d
- SEC Filings10(45%)
- Other6(27%)
- Insider5(23%)
- Leadership1(5%)
Latest news
25 items- PRImageneBio Appoints Matt Robbins as General CounselSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene" or the "Company")), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions, providing strategic counsel as the Company advances its lead candidate, IMG-007. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, PhD, Chief Executive Officer of Imagene. "Matt’s experience building a legal function inside a clinical-
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by ImageneBio Inc.8-K - ImageneBio, Inc. (0001835579) (Filer)
- INSIDERSEC Form 4 filed by Director Bonita David P4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Director Wang Jonathan Jian4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Director Stampacchia Otello4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Director Slattery Joseph P4 - ImageneBio, Inc. (0001835579) (Issuer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECImageneBio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New YorkSAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings. Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 424B3 filed by ImageneBio Inc.424B3 - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form 10-Q filed by ImageneBio Inc.10-Q - ImageneBio, Inc. (0001835579) (Filer)
- SECImageneBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - ImageneBio, Inc. (0001835579) (Filer)
- PRImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program UpdateSAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds of approximately $30 million led by new investor, Coastlands Capital, with participation from Trails Edge Capital Partners and existing investors Omega Funds and OrbiMed, among others. The financing extends the Company's cash runway into the first quarter of 2028 and enables
- SECSEC Form DEFA14A filed by ImageneBio Inc.DEFA14A - ImageneBio, Inc. (0001835579) (Filer)
- SECSEC Form DEF 14A filed by ImageneBio Inc.DEF 14A - ImageneBio, Inc. (0001835579) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ImageneBio Inc.SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
- SECSEC Form SCHEDULE 13D filed by ImageneBio Inc.SCHEDULE 13D - ImageneBio, Inc. (0001835579) (Subject)
- INSIDERSEC Form 3 filed by new insider Lally Robert B3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 3 filed by new insider Su Wei-Guo3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Bonita David P4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - ImageneBio, Inc. (0001835579) (Issuer)
IMA FAQ
6 questionsWhere does IMA stock trade?
ImageneBio Inc. (IMA) is listed on NASDAQ.What sector and industry is IMA in?
ImageneBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImageneBio Inc. go public?
ImageneBio Inc. (IMA) completed its IPO in 2021.What are analysts saying about IMA?
ImageneBio Inc. has had 2 recent analyst actions on file. The most recent action was from Wedbush: Underperform with a $200.00 price target on 2025-11-25.What companies are similar to IMA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IMA side-by-side with any of them on Quantisnow.How can I track IMA on Quantisnow?
Quantisnow aggregates ImageneBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMA to receive live email and push alerts on every new disclosure.